Comparative Pharmacology
Head-to-head clinical analysis: ELTROMBOPAG versus NPLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELTROMBOPAG versus NPLATE.
ELTROMBOPAG vs NPLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Eltrombopag is a small-molecule agonist of the thrombopoietin (TPO) receptor, activating the JAK/STAT signaling pathway to stimulate megakaryocyte proliferation and differentiation, thereby increasing platelet production.
Thrombopoietin receptor agonist that binds to and activates the thrombopoietin receptor (c-Mpl), stimulating megakaryocyte proliferation and differentiation, leading to increased platelet production.
50 mg orally once daily; adjust dose based on platelet response. Maximum dose 75 mg/day.
1 mcg/kg subcutaneously once weekly, based on actual body weight.
None Documented
None Documented
~21–32 hours in healthy subjects; 26–35 hours in ITP patients. Supports once-daily dosing.
Clinical Note
moderateEltrombopag + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Eltrombopag."
Clinical Note
moderateEltrombopag + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Eltrombopag."
Clinical Note
moderateEltrombopag + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Eltrombopag."
Clinical Note
moderateEltrombopag + Ticlopidine
Terminal half-life is 1–2 days (median 1.4 days) after weekly SC dosing; supports weekly administration.
Fecal (≥59% as unchanged drug, ~31% as metabolites); renal (~20% as metabolites, <1% as unchanged drug). Total excretion: feces ~88%, urine ~13%.
Renal excretion is minimal (<5% as unchanged drug); metabolism is expected via proteolysis to small peptides and amino acids; no biliary/fecal data available.
Category C
Category C
Thrombopoietin Receptor Agonist
Thrombopoietin Receptor Agonist
"The metabolism of Ticlopidine can be decreased when combined with Eltrombopag."